HEARTPOINT GLOBAL INC
IntelliStent: A minimally Invasive, Adjustable Pulmonary Flow Restrictor System for Congenital and Acquired Heart Disease
IntelliStent: A minimally Invasive, Adjustable Pulmonary Flow Restrictor System for Congenital and Acquired Heart Disease is a funding opportunity from HEARTPOINT GLOBAL INC, up to 1771084, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
ABSTRACT HeartPoint Global’s IntelliStent is the first minimally invasive, adjustable pulmonary flow restrictor developed for pediatric and congenital heart disease (CHD) patients. Treatments to modify pulmonary flow in the pediatric and CHD populations are currently limited to open-chest pulmonary artery banding…